Cardiovascular Systems, Inc., a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.
Cardiovascular Systems Stock Performance
Shares of Cardiovascular Systems stock opened at $15.71 on Wednesday. The firm has a market cap of $640.73 million, a price-to-earnings ratio of -16.54 and a beta of 0.94. The stock's 50-day moving average is $15.16 and its 200-day moving average is $17.79. Cardiovascular Systems has a one year low of $13.41 and a one year high of $38.52. The company has a debt-to-equity ratio of 0.08, a current ratio of 6.05 and a quick ratio of 5.19.
Insider Activity
In other news, CFO Jeffrey S. Points purchased 3,000 shares of the business's stock in a transaction dated Friday, May 20th. The shares were bought at an average cost of $14.50 per share, for a total transaction of $43,500.00. Following the completion of the acquisition, the chief financial officer now directly owns 109,312 shares in the company, valued at approximately $1,585,024. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 3.40% of the company's stock.